It is known that the College of American Pathologists in 2023 released updates to the templates for reporting biomarker testing results in primary invasive breast carcinomas and in recurrent and metastatic tumors, which now include notes for low expression of the HER2 biomarker (HER2-low) [35]. This evidence concerns the gene ERBB2 and invasive breast carcinoma.